Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Election of Directors. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.

Appointment of Director

On March13, 2017, Richard A. Edlin was appointed to the board of
directors, or the Board, of Eagle Pharmaceuticals,Inc., or the
Company, effective March17, 2017. Mr.Edlins appointment filled a
preexisting vacancy on the Board. Mr.Edlin will serve as a ClassI
director with a term of office expiring at the Companys 2018
annual meeting of stockholders.

In addition, the Board appointed Mr.Edlin to serve as a member of
the nominating and corporate governance committee of the Board,
effective March17, 2017. Following Mr.Edlins appointment, the
members of the nominating and corporate governance committee will
consist of Sander Flaum (Chair), Robert Glenning, and Mr.Edlin.

In connection with his appointment to the Board, the Company will
grant Mr.Edlin an option to purchase 10,000 shares of the
Companys common stock at an exercise price equal to the fair
market value of the Companys common stock on March17, 2017, which
option is subject to annual vesting over three years and will
vest in full upon a change of control of the Company.

The Company has also entered into its standard form of
indemnification agreement with Mr.Edlin.

Item 7.01 Regulation FD Disclosure.

On March16, 2017, the Company issued a press release regarding
the information referenced above, which is attached as
Exhibit99.1 to this Current Report on Form8-K and incorporated
herein by reference.

The information furnished to Item 7.01 of this current report,
including Exhibit99.1, shall not be deemed to be filed for the
purposes of Section18 of the Securities Exchange Act of 1934, as
amended. As such, this information shall not be incorporated by
reference into any of the Companys reports or other filings made
with the Securities and Exchange Commission. The furnishing of
the information in this current report is not intended to, and
does not, constitute a determination or admission by the Company
that the information in this current report is material or
complete, or that investors should consider this information
before making an investment decision with respect to any security
of the Company.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

About Eagle Pharmaceuticals, Inc. (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas.

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) Recent Trading Information

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) closed its last trading session up +0.69 at 34.34 with 9,118,249 shares trading hands.